News | Radiopharmaceuticals and Tracers | February 16, 2017

Cerveau Technologies Signs Manufacturing Agreement with Siemens’ PETNET Solutions for Investigational Tau Imaging Agent

MK-6240 doses for Alzheimer’s-related clinical trial to be manufactured and supplied by PETNET Solutions’ locations in the U.S.

February 16, 2017 — Cerveau Technologies Inc. announced it has signed an agreement with Siemens’ PETNET Solutions Inc. that grants the company the right to manufacture [F-18]MK-6240, an early-stage investigational poistron emission tomography (PET) imaging agent. [F-18]MK-6240 is currently being evaluated to image neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.

Under the terms of its agreement with Cerveau, Siemens’ PETNET Solutions Inc. will initially manufacture [F-18]MK-6240 clinical trial material at select U.S. radiopharmacies, with the possibility of expanding into additional locations.

Siemens’ PETNET Solutions Inc. operates a large network of PET radiopharmaceutical drug manufacturing facilities and dispensing nuclear pharmacies, with over 50 locations worldwide. The company manufactures and dispenses PET radiopharmaceuticals for hospitals, clinics and research facilities worldwide.

For more information:  www.usa.healthcare.siemens.com

Related Content

After radiosurgery concurrent with nivolumab in 59-year-old patient with melanoma BM (patient 1; Supplemental Tables 3 and 5), F-18 FET PET at follow-up 12 weeks after treatment initiation (bottom row) shows significant decrease of metabolic activity (TBRmean, ?28%) compared with baseline (top row), although MRI changes were consistent with progression according to iRANO criteria. Reduction of metabolic activity was associated with stable clinical course over 10 mo. CE = contrast-enhanced. Image created by

After radiosurgery concurrent with nivolumab in 59-year-old patient with melanoma BM (patient 1; Supplemental Tables 3 and 5), F-18 FET PET at follow-up 12 weeks after treatment initiation (bottom row) shows significant decrease of metabolic activity (TBRmean, ?28%) compared with baseline (top row), although MRI changes were consistent with progression according to iRANO criteria. Reduction of metabolic activity was associated with stable clinical course over 10 mo. CE = contrast-enhanced. Image created by N. Galldiks et al., Research Center Juelich, Juelich, Germany.

News | PET Imaging | May 05, 2021
May 5, 2021 — For patients with brain metastases, amino acid ...
The emergence of #therapeutic #radiopharmaceuticals and its adoption in #cancer care provide one more weapon in combating cancer

Getty Images

Feature | Radiation Oncology | May 04, 2021 | By Vinay Shivaprasad
The term nuclear medicine is associated with the diag
olecular Targeting Technologies, Inc. (MTTI) announced the issuance of United States Patent # 10,953,113. The patent claims a quick (5 min), easy and quantitative conversion of commercially available 18F-deoxyglucose (18F-FDG) to 18F-Fluroglucaric acid (18F-FGA).

Getty Images

News | PET Imaging | April 19, 2021
April 19, 2021 — Molecular Targeting Technologies, Inc.
The inflamed joints of a #rheumatoid #arthritis patient are clearly visible in the #PET images with the novel 68Ga-DOTA-Siglec-9 #radiopharmaceutical. Image courtesy of Anne Roivainen

The inflamed joints of a rheumatoid arthritis patient are clearly visible in the PET images with the novel 68Ga-DOTA-Siglec-9 radiopharmaceutical. Image courtesy of Anne Roivainen

News | PET Imaging | April 19, 2021
April 19, 2021 — The preliminary...
#NorthStar Medical #Radioisotopes, LLC, a global innovator in the development, production and commercialization of #radiopharmaceuticals used for #medicalimaging and #therapeutic applications, announced a corporate update highlighting progress across its key programs during the past twelve months and upcoming milestones.

NorthStar Medical Radioisotopes, Beloit, Wisconsin campus (Photo: Business Wire)

News | Radiopharmaceuticals and Tracers | April 16, 2021
April 16, 2021 — ...
Shine executives are joined by the company’s construction managers and partners at its medical isotope production facility. The group was commemorating the facility’s achievement of weathertight status

Shine executives are joined by the company’s construction managers and partners at its medical isotope production facility. The group was commemorating the facility’s achievement of weathertight status. Image courtesy of Shine Medical Technologies

News | Radiopharmaceuticals and Tracers | March 26, 2021
March 26, 2021 — Shine Medical Technologies LLC announced that construction of the exterior structure of its first-of
The phantom used for hyperpolarized imaging, with an illustration of imaging slices acquired using the new technique. photo/©: Laurynas Dagys, University of Southampton

The phantom used for hyperpolarized imaging, with an illustration of imaging slices acquired using the new technique. photo/©: Laurynas Dagys, University of Southampton

News | Nuclear Imaging | March 12, 2021
March 12, 2021 — Magnetic resonance imaging (MRI)
Diagnostic imaging studies using Tc-99m inform healthcare decisions for approximately 30 million patients annually around the world
News | Nuclear Imaging | March 08, 2021
March 8, 2021 — IBA (Ion Beam Applications S.A., EURONEXT) an